 Connection
Petter Bjornstad to Glucosides
This is a "connection" page, showing publications Petter Bjornstad has written about Glucosides.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.220 |
|
|
|
-
van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
Score: 0.236
-
Bjornstad P, Choi YJ, Narongkiatikhun P, Karihaloo A, Prasad PV, Li LP, Tommerdahl KL, Sethi M, Ramesh S, Birznieks C, Clarke A, Elia Y, Curtis J, Clarson C, Weissenkampen D, D'Antonio M, Pinzon Cortes JA, Hampson H, Yuan L, van Eeghen SA, Kanter JE, Bornfeldt KE, Vaisar T, Ladd P, Heerspink HJL, de Boer IH, Goodrich JA, Street K, Tuttle KR, Bergmann KR, Smith C, Hodgin JB, Schaub JA, Nair V, Menon R, Naik AS, McCown PJ, AlAkwaa F, Eddy S, Otto E, Kim NH, Nelson RG, Puelles VG, van Raalte DH, Cherney DZI, Pyle L, Mahmud FH, Kretzler M. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Sci Transl Med. 2026 Jul 22; 18(859):eaee1005.
Score: 0.236
-
Anthony SJ, Selkirk EK, Pol SJ, Lin J, Bui S, Bjornstad P, Clarson C, Clarke A, Curtis J, Elia YT, McArthur L, Mertens L, Moineddin R, Kirsch S, Coles N, Maione M, Furman M, Babalola F, Tommerdahl KL, Harrington J, Riddell MC, Prasad P, Heerspink HJL, Cherney DZI, Mahmud FH. Adolescents With Type 1 Diabetes Using Dapagliflozin as an Adjunct-to-Insulin: Perspectives on Experiences of Clinical Trial Participation. Endocr Pract. 2026 Apr; 32(4):583-590.
Score: 0.227
-
Mahmud FH, Bjornstad P, Clarson C, Clarke A, Anthony SJ, Curtis J, Elia YT, McArthur L, Mertens L, Moineddin R, Kirsch S, Coles N, Maione M, Furman M, Babalola F, Tommerdahl KL, Harrington J, Riddell MC, Prasad P, Huang L, Heerspink HJL, Cherney DZI. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat Med. 2025 Jul; 31(7):2317-2324.
Score: 0.218
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 07; 27(7):3943-3956.
Score: 0.217
-
Kugathasan L, Sridhar VS, Lovblom LE, Matta S, Saliba A, Debnath S, AlAkwaa FM, Nair V, Bjornstad P, Kretzler M, Perkins BA, Sharma K, Cherney DZI. Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 Diabetes. Diabetes. 2024 Mar 01; 73(3):401-411.
Score: 0.200
-
Tommerdahl KL, Nelson RG, Bjornstad P. Dapagliflozin in young people with type 2 diabetes. Lancet Diabetes Endocrinol. 2022 05; 10(5):303-304.
Score: 0.175
-
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Kidney Effects of Empagliflozin in People with Type 1 Diabetes. Clin J Am Soc Nephrol. 2021 11; 16(11):1715-1719.
Score: 0.169
-
Bjornstad P, Nelson RG, Pavkov ME. Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes? Kidney Int. 2020 01; 97(1):31-33.
Score: 0.150
-
Rajasekeran H, Reich HN, Hladunewich MA, Cattran D, Lovshin JA, Lytvyn Y, Bjornstad P, Lai V, Tse J, Cham L, Majumder S, Bowskill BB, Kabir MG, Advani SL, Gibson IW, Sood MM, Advani A, Cherney DZI. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol. 2018 03 01; 314(3):F412-F422.
Score: 0.129
-
Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 Oct 24; 136(17):1643-1658.
Score: 0.129
-
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obes Metab. 2025 08; 27(8):4415-4426.
Score: 0.054
-
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
Score: 0.044
-
van Bommel EJM, Ruiter D, Muskiet MHA, van Baar MJB, Kramer MHH, Nieuwdorp M, Joles JA, Bjornstad P, van Raalte DH. Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function. Diabetes Care. 2020 01; 43(1):228-234.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|